These can increase the risk of tooth decay and gum disease
And it's a series of studies with different designs and populations to look, in randomized controlled trials that's the highest level evidence at what this drug would do for individuals with obesity, individuals with obesity who also had diabetes, what about if we add intensive lifestyle therapy to it, what would happen if we stopped the medication, what about individuals living with arthritis or with heart failure or heart disease

Heres what it means for Medicaid enrollees: Medicaid access through the BALANCE Model could begin as early as May 2026 States must opt in voluntarily its not automatic Participating states receive federally negotiated prices from Eli Lilly (Zepbound, Mounjaro) and Novo Nordisk (Wegovy, Ozempic) Wegovy and Zepbound starting doses would cost the program $350/month (reduced from over $1,000) Patients in participating states would pay $50/month for covered GLP-1s Prior authorization and qualifying criteria will still apply This is the biggest potential expansion of GLP-1 access for Medicaid enrollees in history but it depends on your state deciding to participate
Examination of actin-binding and cell-migration activity of Thymosin Beta-4 (TB-500) in wound-healing and cardiac-tissue research models, including comparison against single-peptide TB-500 reference material
Two hundred microliters of the inoculated API 50 CHB/E medium were added into the strip wells and incubated for 48 h
The evidence suggests that specific GLP1-RAs have differing effects, primarily on weight reduction and glucose-lowering